Pulmatrix Q3 net loss $877K; pursues asset divestment for Cullgen merger

Pulmatrix, Inc.

2025-Q3 EPS reported -$1.16

Net loss $877K ($0.24 per share); revenues $0 vs $0.4M YoY; cash $4.8M sufficient into Q4 2026.
Pursuing divestment of iSPERSE technology and clinical programs (PUR3100, PUR1800, PUR1900) ahead of proposed Cullgen merger.
Proposed merger with Cullgen stockholder-approved; closing subject to Nasdaq & China regulatory approval.
R&D expenses fell to <$0.1M; G&A down to $0.9M due to winddown and cost cuts.
PUR3100 Phase 2 ready for acute migraine; PUR1900 partner Cipla advancing Phase 3 in India.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.